Mutations in the optineurin (OPTN) gene have been implicated in both familial and sporadic amyotrophic lateral sclerosis (ALS). However, the role of this protein in the central nervous system (CNS) and how it may contribute to ALS pathology are unclear. Here, we found that optineurin actively suppressed receptor-interacting kinase 1 (RIPK1)-dependent signaling by regulating its turnover. Loss of OPTN led to progressive dysmyelination and axonal degeneration through engagement of necroptotic machinery in the CNS, including RIPK1, RIPK3, and mixed lineage kinase domain-like protein (MLKL). Furthermore, RIPK1-and RIPK3-mediated axonal pathology was commonly observed in SOD1
John Ravits, 3, 4 Junying Yuan 1,5 * Mutations in the optineurin (OPTN) gene have been implicated in both familial and sporadic amyotrophic lateral sclerosis (ALS). However, the role of this protein in the central nervous system (CNS) and how it may contribute to ALS pathology are unclear.
Here, we found that optineurin actively suppressed receptor-interacting kinase 1 (RIPK1)-dependent signaling by regulating its turnover. Loss of OPTN led to progressive dysmyelination and axonal degeneration through engagement of necroptotic machinery in the CNS, including RIPK1, RIPK3, and mixed lineage kinase domain-like protein (MLKL). Furthermore, RIPK1-and RIPK3-mediated axonal pathology was commonly observed in SOD1 G93A transgenic mice and pathological samples from human ALS patients. Thus, RIPK1 and RIPK3 play a critical role in mediating progressive axonal degeneration. Furthermore, inhibiting RIPK1 kinase may provide an axonal protective strategy for the treatment of ALS and other human degenerative diseases characterized by axonal degeneration.
L
oss-of-function mutations in the optineurin (OPTN ) gene have been implicated in both familial and sporadic cases of amyotrophic lateral sclerosis (ALS), a devastating degenerative motor neuron disease (1) (2) (3) . The Optn gene encodes a ubiquitin-binding protein involved in tumor necrosis factor-a (TNFa) signaling but is dispensable for nuclear factor kB (NF-kB) activation (4, 5) . It is still unclear how the loss of function of OPTN leads to human ALS.
Receptor-interacting kinase 1 (RIPK1) is a critical regulator of cell death and inflammation (6) . RIPK1 regulates necroptosis, a form of regulated necrotic cell death, by promoting the sequential activation of two downstream targets, RIPK3 and mixed lineage kinase domain-like protein (MLKL) (7) (8) (9) . Application of necrostatin-1 (7-Cl-O-Nec-1) (Nec-1s), a highly specific inhibitor of RIPK1 kinase activity, blocks necroptosis and inflammation in vitro and in vivo (10, 11) . However, the pathophysiological significance of RIPK1 and necroptosis in the genetic context of human diseases remains to be established.
ALS belongs to axonal "dying back" neurodegenerative diseases, as the onset begins with axonal pathology. Axonal degeneration makes a substantial contribution to neurological disability in these patients (12) . Axonal degeneration induced by direct nerve injury-known as Wallerian degeneration-is mediated through a mechanism distinct from apoptosis of neuronal cell bodies (13, 14) . Axonal degeneration in patients with neurodegenerative diseases such as ALS may also exhibit features similar to those of Wallerian degeneration and is referred to as "Wallerian-like" degeneration. The mechanism of Wallerian or Wallerian-like degeneration is still unclear.
To understand the mechanism by which the loss of OPTN could lead to ALS, we developed Optn -/-mice ( fig. S1, A To determine the cell types involved in mediating Optn deficiency-induced axonal degeneration, we generated lineage-specific deletion of Optn using Cnp-cre, Lyz2-cre, Gfap-cre, and Mnx1-cre mice (16) (17) (18) We found that knockdown of Optn sensitized cells to necroptosis in our genome-wide small interfering RNA screen (20, 21) (Z-score = -2.07) (table S1). We further confirmed that knockdown of Optn sensitized L929 cells to necroptosis induced by TNFa or zVAD.fmk ( fig. S4, A and B) . zVAD-induced necrosis is known to involve autocrine TNFa activity (22) . Thus, Optn deficiency sensitized cells to necroptosis ( fig. S4C) Optn-/-;
Chd7 Vegfa The top 71 genes in this module include CD14 and CD86, biomarkers for the proinflammatory M1-like state (26) (Fig. 2I and table S2 ). Elevated CD14 and CD86 in Optn -/-microglia were suppressed by Nec-1s and Ripk1  D138N/D138N (fig. S5C ). Thus, Optn deficiency promotes an M1-like inflammatory microglia.
We analyzed the genes differentially expressed in Optn -/-microglia using MSigDB (Molecular Signatures Database) (27) to identify transcription factors with targets that were overrepresented. We found a significant overrepresentation of the predicted Sp1 transcription factor targets in the ME1 module (table S3) ;Ripk3 -/-doublemutant mice and by Nec-1s (Fig. 3, A to E) . Behaviorally, Optn -/-mice showed no difference in total locomotor activity, whereas the vertical rearing activity was significantly reduced compared with that of WT mice (Fig. 3, F To explore the involvement of RIPK1-mediated axonal pathology in ALS in general, we used SOD1 G93A transgenic mice. Oligodendrocytes in SOD1 G93A mice degenerate early, but the mechanism is unclear (29) . We found that the expression of Ripk1, Ripk3, and MLKL in the spinal cords of SOD1 G93A transgenic mice was elevated (Fig. 4A ). In addition, we observed a similar axonal pathology as that of Optn -/-mice in SOD1 G93A mice before the onset of motor dysfunction (Fig. 4, B and C) . Furthermore, these axonal myelination defects were blocked and motor dysfunction onset was delayed genetically by Ripk3 knockout or by oral administration of Nec-1s (Fig. 4, D and E) . Thus, although we cannot rule out the contribution of Ripk1 or other proapoptotic factors to the degeneration of motor neuron cell bodies (30, 31) , the activation of necroptosis contributes to axonal pathology and motor dysfunction in the SOD1 G93A transgenic mice.
We next characterized the role of RIPK1 and necroptosis in human ALS. We found evidence of demyelination in the lateral column white matter of lower spinal cord pathological samples from ALS patients as reported (Fig. 4F) . In human ALS pathological samples, we also detected multiple biochemical hallmarks of necroptosis, including increased levels of RIPK1, RIPK3, and MLKL and increased RIPK1 p-Ser 14/15 and p-MLKL in both microglia and oligodendrocytes (Fig. 4G,  fig. S7, and table S4 ). Note that p-MLKL was primarily localized in the white matter, where demyelination was found.
Taken together, our results provide a direct connection between Wallerian-like degeneration induced by OPTN deficiency and RIPK1-regulated necroptosis and inflammation. By promoting both inflammation and cell death, RIPK1 may be a common mediator of axonal pathology in ALS ( fig. S8 ). Because RIPK1 is recruited specifically to the TNF receptor TNFR1 to mediate the deleterious effect of TNFa (32) , blocking RIPK1 may provide a therapeutic option for the treatment of ALS without affecting TNFR2. Finally, given the recruitment of OPTN to intracellular protein aggregates found in pathological samples from patients with Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jakob disease, multiple system atrophy, and Pick's disease (33, 34) , a possible role of RIPK1 in mediating the wide presence of axonal degeneration in different neurodegenerative diseases should be considered.
